Susan Dexter is Director at Sonnet BioTherapeutics Holdings, Inc. (SONN). They have made 1 open-market trade across 1 company since 2023, most recently 2025-12-02.
CIK 0001806764
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $7K since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SONN | 9,643 | $12K |
Shares reported on the most recent Form 4, priced at the 2025-07-15 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SONN | BUY | 2023-06-14 | 2023-06-15 | $0.70 | $7K | -47.5% | -56.1% | -83.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.